Visiox Pharmaceuticals announces merger with Ocuvex Therapeutics

(Image credit: AdobeStock/yalcinsonat)

Visiox Pharmaceuticals Inc announced it has entered into a definitive merger agreement with Ocuvex Therapeutics Inc.

According to a news release, Ocuvex, a privately held ophthalmic pharmaceutical company focused on developing and commercializing novel therapies for glaucoma and other disorders, has a pipeline of near-term ophthalmic medicines.¹

The companies noted the strategic combination will position the newly combined entity as a potential leader in the eye care sector with a portfolio of ophthalmic medicines.

Visiox's products include omidenepag isopropyl ophthalmic solution (Omlonti), licensed by Visiox from Santen Pharmaceuticals a year ago. Another, PDP-716 (brimonidine) 0.35%, is the next closest to the market. It is a once-daily solution that the company has been hoping to launch in early 2025. It also has SDN-037 (difluprednate) 0.04%, which will grow Ocuvex's market presence and accelerate the commercialization of these therapeutics.¹

Going forward, the company will operate under the Ocuvex name, building on Visiox's commitment to disrupting the ophthalmic market through high-level collaboration with eye care professionals.

"The combination of Visiox and Ocuvex makes for a perfect match," Ryan S. Bleeks, CEO of Visiox, said in the news release. "We have reached significant milestones with our products and Ocuvex is in a great position to take these advancements forward and bring them to market faster and emerge as a future leader in eye care."

Reference:

1. Visiox Pharmaceuticals, Inc. Visiox Pharmaceuticals, Inc. Announces Transformative Merger with Ocuvex Therpeutics, Inc. Prnewswire.com. Published August 19, 2024. Accessed August 19, 2024. https://www.prnewswire.com/news-releases/visiox-pharmaceuticals-inc-announces-transformative-merger-with-ocuvex-therpeutics-inc-302224689.html